

Dr Jane Kaye and Naomi Hawkins
Ethox Centre
University of Oxford





wellcometrust

### **Structure of Talk**

- Current situation and changes in research practice
- Types of IP that might apply to biobanks
- Examples of models that have been used
- Ways Forward





## **Changes in Research Practice**

- Movement from isolated biobanks to networks of biobanks
- Recognition of the need for sharing of data and samples
  - -Tension between recognition of individual contributions and data-sharing
- These changes have been supported by technological advances





- Convergence of the aims of commercial and non-profit organisations
  - –Human Genome Project; HapMap; 1000Genomes Project
- Little empirical research on:-
  - The relationship between data sharing and innovation
  - How IP effects the translation of research results into clinical practice
- Few biobanks have Intellectual Property policies in place, but all agree that it is necessary







# What are the Intellectual Property Tools for Biobanks?

- Database protection
- Copyright
- Trade Secrets
- Patents





#### **Database Protection**

- Directive 96/9 on the Legal Protection of Databases
  - Europe only
- Protects from unauthorised reproduction of the database
- It is a right that is potentially unlimited, as each time the database is modified, the clock starts again









## Copyright

- Broad international standards (Berne Convention and TRIPs) implemented in national legislation
- Protects the 'expression of an idea'
  - the way in which data is presented
  - -Consent forms are written
  - -Compilations of information in some jurisdictions
- Limited application to freely accessible biobanks










#### **Trade Secrets**

- Derives from the breach of confidence doctrine
- Prohibits the unauthorised disclosure of information that is provided in confidence
- Useful when innovations are being developed but also as an alternative to IP rights

-e.g Coca Cola recipe








#### **Patents**

- Criteria for patentability:
  - New
  - Useful
  - Non-obvious/inventive step
- Whether an invention is new is assessed against the prior art
  - If someone has done it before, you can't have a patent
  - Therefore, making genomic information public reduces the likelihood of someone else patenting it









#### **Patents**

- Inventor may be owner but this can be modified by other agreements e.g. employer will usually own patents on employee inventions
- Patents are often licensed
  - –e.g. University may licence a patent to a pharmaceutical company
  - Licences may be non-exclusive or exclusive









#### **Patents**

- Patents are often viewed as problematic in genetics
  - -Liberal granting of patents by PatentOffices in early years
    - Patents applied for by NIH on ESTs
  - -Concerns about 'royalty stacking'
  - Perception that patents reduce patient access to genetic testing
    - Myriad genetics and breast cancer tests
- However, in practice there is little evidence of enforcement against academic and public sector institutions in Europe at least









#### What does IP do?

- Reward for creativity and the inventor is given a monopoly in return for making the invention public
- IP rights are neutral, it depends how you exercise that right
  - -e.g. Cystic Fibrosis
- Patents have been very effective in encouraging innovation in drug development, but doubts about benefits in other areas
- Despite this, push by institutions and funders to apply for patents because of wellcome trust fear of free -riders and restricting data









## Solutions?







## 'Click and Wrap'

- Could only access raw data if agreed not to take any action that would restrict access to the data
- Superseded by open access policy which put all the data in the public domain
- Not all biobanks would want to put all data in the public domain



## **Structural Genomics** Consortium (SGC)

- Launched 2008 with a consortium of foundations, research institutions and pharmaceutical companies
- Purpose to identify and describe molecules that inhibit reactions in cells that could be used in industrial and academic biomedical research
- Partners agreed that none of them would commercialise the inhibitors and use patent rights to block others from doing so









#### UNITAID

- Established by countries, philantrophic foundations and NGO's
- Purpose to supply essential medicines for HIV/AIDS, malaria and tuberculosis
- Built a patent pool and sponsored a new non-profit agency to manufacture drugs
- Result able to provide essential drugs to those in need in low income countries at a reduced price









## **Basic Principles**

- IPR are tools and it is how we use them and when that is important
- IPR must be understood as just one of the drivers for innovation
- Enthusiastic use of IP can stifle sharing Ethox which is necessary for further innovation
- IP has a marginal role in encouraging research but a significant role in the dissemination of new products and services







# **Ways Forward?**





# Option 1 – DO NOT TRY TO CONTROL IP

- Regard biobanks as resources and open to all
- Separates out research and the commercialisation of innovation
- It is unlikely that there will be huge innovations from the raw data in a biobank
- However, this does not recognise the effort in developing the biobank
  - -Publishing recognition e.g.KORAGEN









# The priorities (?)

- Key aim is to carry out research that will improve our knowledge and understanding of the causes of disease and treatment
  - -This is promoted by data sharing
- To ensure the translation of research knowledge into clinical benefits
  - -IP rights are a part of this







## Option 2 – NEW MODELS

- Need to develop models that promote trust and collaboration at the start
- Need to have input from all the stakeholders
  - Funders, participants, users- both non-profit and commercial, regulatory bodies
- Scope for using IP creatively
- Understand innovation as messy and not linear









### In conclusion

- Establish our priorities
- Biobanking networks at a crucial stage
- Recognise that IP is just one tool to encourage innovation
- Develop models that facilitate data sharing and enable innovation, drawing on skills and participation of all stakeholders









## Recommended Reading

- Toward a New Era of Intellectual Property: From Confrontation to Negotiation September 2008
  - -International Expert Group on Biotechnology, Innovation and Intellectual Property
  - -Led by Richard Gold at Mc Gill University









### **dbGaP**

- NIH sets out aspirational principles in access agreements.
- Eg dbGaP:
  - -The data will be pre-competitive and not be protected by IP
  - Investigators cannot restrict other investigator's use of primary dbGaP data by filing IP
  - -For restricted access data NHGRI discourages the use if patents in a manner that would prevent or block access to any fundamental data that are developed with NHGRI support

Ethox

wellcome trust

 Threat of withdrawal of future funding for failure to comply may be more effective than a legally enforceable agreement

## Memorandum of Understanding

- Basis of collaboration
  - Details expertise bringing to project
  - Distribution of IP benefits
- May have different requirements from different institutions regarding the IP
- Costly and time-consuming
- Problems of cross-border agreements –conflict of laws

